Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pastucovac Vaccine in Post-Allo-HSCT Patients
NCT05185817Phase 2Unknown
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2021
- Primary completion
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Pastucovac in coronavirus disease 2019 (COVID-19), sponsored by Tehran University of Medical Sciences. Primary endpoints: Assessment of COVID-19 vaccine effectiveness and Grade III-IV vaccine-related adverse reactions. Status: unknown.
02
Drugs
Pastucovac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05185817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05185817.